Mission Statement, Vision, & Core Values (2025) of AstraZeneca Pharma India Limited.

An Overview of AstraZeneca Pharma India Limited

General Summary of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca PLC, a global, science-led biopharmaceutical company. Established in 1979, it specializes in the discovery, development, and commercialization of prescription medicines. AstraZeneca operates in several therapeutic areas including oncology, cardiovascular, renal, respiratory, and infectious diseases.

As of 2024, the company offers a variety of products, with key medications such as Tagrisso, Imfinzi, and Farxiga playing significant roles in its portfolio. The company's sales revenue for the fiscal year ending December 2023 reached approximately INR 3,500 crore, marking a substantial increase over the previous year.

Company's Financial Performance in the Latest Financial Reports

In the latest quarterly report for Q2 2024, AstraZeneca Pharma India Limited reported record-breaking revenue of INR 900 crore, which represents a 15% increase from the previous quarter. The primary drivers of this growth were the robust sales of its core products, particularly in oncology and cardiovascular segments.

The following table provides a detailed breakdown of the company's revenue by product for FY 2023:

The growth in sales has been attributed to expanding market presence and increased demand for innovative therapies, particularly in urban centers where healthcare access is improving.

Introduction to Company as a Leader in the Industry

AstraZeneca Pharma India Limited stands as a leader in the pharmaceutical industry, recognized for its commitment to research and development. The company invests over 15% of its revenue into R&D annually, focusing on innovative solutions that address unmet medical needs.

As a part of its growth strategy, AstraZeneca has strengthened its presence in emerging markets and enhanced its portfolio through strategic collaborations and acquisitions. The company's strong focus on sustainability and ethical practices further bolsters its reputation in the industry.

Investors and stakeholders are encouraged to explore more about AstraZeneca's successful strategies by reviewing their comprehensive annual reports and financial disclosures available on their website.

Mission Statement of AstraZeneca Pharma India Limited

Mission Statement of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited's mission statement encapsulates its commitment to delivering innovative, high-quality healthcare solutions. This mission is a guiding light for the company's long-term goals and strategies, emphasizing patient-centric innovations while maintaining ethical standards in its operations.

Core Component 1: Innovation

AstraZeneca prioritizes innovation in drug development and healthcare solutions. In 2022, the company invested approximately USD 6.3 billion in research and development globally, which represents 26% of its total revenue. This dedication enables the company to address unmet medical needs with new therapies.

Core Component 2: Quality

Quality assurance is fundamental to AstraZeneca's operations. The company employs a robust quality management system across its manufacturing facilities. As of 2023, AstraZeneca India achieved a compliance rate of 98.5% in regulatory inspections, demonstrating its commitment to maintaining high standards in product quality.

Core Component 3: Sustainability

AstraZeneca is committed to minimizing its environmental footprint. By 2025, the company aims to be carbon negative across its global operations. In 2022, it reported a 25% reduction in greenhouse gas emissions compared to 2015 levels. Through sustainable practices, AstraZeneca is taking significant steps to contribute positively to global health and the environment.

Vision Statement of AstraZeneca Pharma India Limited

Vision Statement Overview

AstraZeneca Pharma India Limited aims to be a leading biopharmaceutical company committed to providing innovative medicines that improve the health and quality of life for patients in India and around the world. The vision encapsulates a future where they can address unmet medical needs through cutting-edge research and development.

Innovation in Biopharmaceuticals

The core of AstraZeneca's vision lies in relentless innovation. The company has invested ₹ 1400 crore in research and development as of 2023. This investment facilitates the development of new therapies across various disease areas, including oncology, respiratory diseases, and cardiovascular health.

Patient-Centric Approach

AstraZeneca’s vision emphasizes a patient-centric approach. In 2023, they reported a 20% increase in patient enrollment for clinical trials compared to the previous year. This reflects their commitment to understanding patient needs and improving access to healthcare solutions.

Global Health Contribution

AstraZeneca aims to contribute to global health initiatives, pledging to deliver over 200 million doses of vaccines and medicines to underserved populations by 2025. This goal underscores their dedication to equitable healthcare access.

Commitment to Sustainability

The vision encompasses a strong focus on sustainability, with AstraZeneca setting an ambitious target to achieve carbon neutrality by 2025. The company has reduced its carbon footprint by 30% in its operations since 2019, showcasing a commitment to responsible manufacturing and environmental stewardship.

Strategic Partnerships

AstraZeneca recognizes the importance of strategic partnerships in realizing its vision. In 2023, they entered into collaborations with over 10 research institutions and non-profit organizations, facilitating knowledge exchange and resource sharing in drug development.

Core Values of AstraZeneca Pharma India Limited

Integrity

AstraZeneca Pharma India Limited prioritizes integrity in all aspects of its operations. This core value underlines the importance of honesty, accountability, and ethical practices.

In 2023, AstraZeneca reinforced its commitment to integrity through numerous initiatives. The company implemented a new ethics training program that reached over 10,000 employees, emphasizing compliance with global standards and regulations.

Innovation

Innovation is central to AstraZeneca’s strategy, driving both its research and development efforts as well as operational improvements.

In 2024, AstraZeneca invested ₹1,500 crore in R&D focusing on next-generation therapies, reflecting a significant commitment to pioneering advancements in pharmaceuticals.

• Launched 3 new products in the oncology sector
• Increased patent filings by 20% year-over-year
• Collaboration with over 15 academic institutions for innovative drug research

Collaboration

Collaboration within the organization and with external stakeholders is vital for AstraZeneca’s success. This value drives team efforts, partnerships, and community engagement.

In 2024, AstraZeneca established strategic alliances with 10 global biotech firms to enhance its product pipeline.

Respect

Respect for individuals and the environment is a fundamental core value at AstraZeneca. The company aims to create an inclusive workplace and sustainable practices.

In 2024, AstraZeneca achieved 50% gender diversity in its leadership roles, fostering an inclusive culture throughout the organization.

• Implemented flexible work arrangements for 2,500 employees
• Launched sustainability initiatives reducing carbon emissions by 30% in manufacturing
• Conducted over 100 community outreach programs to promote health and education

Patient-Centricity

At the heart of AstraZeneca’s operations is a strong commitment to patient-centricity, ensuring that patient needs drive the company's decisions and innovations.

In 2024, AstraZeneca launched a new digital health platform aimed at improving patient engagement, with an initial reach of over 500,000 patients.